COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries27/06/2017
-   
  Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA27/06/2017
-   
  Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe27/06/2017
-   
  Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union27/06/2017
-   
  Sanofi et Regeneron annoncent l'approbation de Kevzara® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte27/06/2017
-   
  ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA27/06/2017
-   
  Ossur Hf : Transactions in relation to share buyback program26/06/2017
-   
  Sanofi : Disclosure of trading in own shares26/06/2017
-   
  Sanofi : Déclaration des transactions sur actions propres26/06/2017
-   
  Scientific breakthrough on objective diagnosis of PTSD26/06/2017
-   
  Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients26/06/2017
-   
  Novo Nordisk A/S - Share repurchase programme26/06/2017
-   
  Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units26/06/2017
-   
  Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL26/06/2017
-   
  ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS26/06/2017
-   
  INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma's governance and management team26/06/2017
-   
  INNATE PHARMA : Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société26/06/2017
-   
  Bone Therapeutics SA: Receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform26/06/2017
-   
  Bone Therapeutics SA: Reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique26/06/2017
Pages